Hunogidon 28 (Desogestrel, Ethinylestradiol | Lactose Anhydrous)

Hunogidon 28 is indicated for women who require reliable hormonal contraception. It may be prescribed as a primary method of birth control for individuals seeking a reversible, non‑sterilizing option.

• Prevents pregnancy when taken as directed.
• Provides cycle control and reduces the risk of ovulation‑related disorders.
• May be used in women with regular menstrual cycles who have no contraindications to estrogen‑containing contraceptives.
• Can be part of a combined hormonal regimen that includes other estrogen or progestin products under medical supervision.
• Offers a convenient once‑daily oral dosing schedule.

• Desogestrel is a progestogenic agent that binds to progesterone receptors, suppressing the mid‑cycle surge of luteinizing hormone and thereby inhibiting ovulation. Ethinylestradiol is a synthetic estrogen that provides negative feedback on the hypothalamic‑pituitary axis, reducing follicle‑stimulating hormone release and stabilizing the endometrial lining. Together, the two hormones also thicken cervical mucus, creating a hostile environment for sperm penetration and thus preventing fertilization.

Like all hormonal contraceptives, Hunogidon 28 may cause unwanted effects, most of which are mild and transient in many users.

Common

• Nausea or mild stomach upset.
• Headache, including tension‑type pain.
• Breast tenderness or slight enlargement.
• Irregular spotting or breakthrough bleeding.

Serious

• Deep vein thrombosis or pulmonary embolism.
• Severe hypertension or hypertensive crisis.
• Allergic reactions such as rash, swelling, or anaphylaxis.

Before prescribing Hunogidon 28, clinicians should evaluate individual risk factors and contraindications to ensure safe use in each patient carefully.

• History of thromboembolic disorders, such as deep vein thrombosis or stroke.
• Uncontrolled hypertension, cardiovascular disease, or smoking over 15 cigarettes per day.
• Current or past breast cancer, estrogen‑dependent tumors, or liver disease.
• Known or suspected pregnancy, as the product is not indicated for use during gestation.
• Use of combined hormonal contraceptives with other estrogen‑containing therapies without medical supervision.

Hunogidon 28 can interact with several medicines, altering its effectiveness or increasing the risk of adverse events for the patient.

Avoid

• Strong enzyme inducers such as rifampin, carbamazepine, or phenytoin, which may reduce contraceptive efficacy.
• Antifungal agents like ketoconazole that increase hormone levels and risk of estrogen‑related side effects.
• St. John’s wort, a herbal supplement known to lower plasma concentrations of oral contraceptives.

Use with caution

• Anticoagulants (e.g., warfarin) where hormonal changes may affect clotting parameters.
• Antihypertensive drugs, especially ACE inhibitors or beta‑blockers, requiring blood pressure monitoring.
• Other hormonal therapies, including hormone replacement or menopausal regimens, to avoid excess estrogen exposure.